Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Triple Viable Bifidobacterium
- Development stage
- Unknown
- Lead developer
- Wang Hua
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Triple Viable Bifidobacterium is a probiotic combination therapy consisting of live *Bifidobacterium longum*, *Lactobacillus acidophilus*, and *Enterococcus faecalis*. It is primarily used as a microbiome-modulating agent to regulate intestinal flora and improve gastrointestinal health. In clinical settings, particularly in neonatology, it is administered to preterm infants to facilitate the establishment of normal gut microbiota, which is often delayed due to factors such as antibiotic use, lack of breastfeeding, and delayed enteral feeding. By colonizing the intestinal tract with beneficial bacteria, the therapy aims to enhance the mucosal barrier, inhibit the growth of pathogenic microorganisms, and improve feeding tolerance. Research led by Wang Hua has specifically evaluated its efficacy in reducing feeding intolerance and preventing complications like necrotizing enterocolitis in preterm infants.
- Brand names
- PeifeikangBifidobiogen
- Other names
- Bifidobacterium Triple ViableTriple Viable Bifidobacterium, Lactobacillus and EnterococcusBifidobacterium longum + Lactobacillus acidophilus + Enterococcus faecalis
Beyond the preview
Go deeper on Triple Viable Bifidobacterium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Triple Viable Bifidobacterium.